Skip to main content

Market Overview

Myovant Sciences: Q4 Earnings Insights

Share:

 

Shares of Myovant Sciences (NYSE:MYOV) moved higher by 4.5% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share decreased 21.92% over the past year to ($0.89), which beat the estimate of ($0.99).

Revenue of $24,605,000 higher by 0.00% from the same period last year, which missed the estimate of $24,630,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: May 11, 2021

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/h7sgwdvh

Recent Stock Performance

52-week high: $30.90

52-week low: $11.55

Price action over last quarter: down 10.29%

Company Description

Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.

 

Related Articles (MYOV)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com